Literature DB >> 19220461

TioS T-TE--a prototypical thioesterase responsible for cyclodimerization of the quinoline- and quinoxaline-type class of chromodepsipeptides.

Lars Robbel1, Katharina M Hoyer, Mohamed A Marahiel.   

Abstract

The family of chromodepsipeptides constitutes a class of structurally related pseudosymmetrical peptidolactones and peptidothiolactones synthesized by nonribosomal peptide synthetases. The chromodepsipeptides, which are analogous to the extensively characterized echinomycin, attain their DNA-bisintercalating properties from chromophore moieties attached to the N-termini of the oligopeptide chain. Thiocoraline, a quinoline-substituted DNA-bisintercalator isolated from marine actinomycetes, is a two-fold symmetric octathiodepsipeptide currently undergoing preclinical trials phase II. In the present study, the excised peptide cyclase TioS T-TE (thiolation-thioesterase bidomain) was employed as a general catalyst for the in vitro generation of thiocoraline analogs. TioS T-TE is capable of catalyzing ligation and the subsequent cyclization of tetrapeptidyl-thioester substrates, circumventing the demanding synthesis of octapeptidyl substrates. The general importance of several amino acid residues within the tetrapeptide was evaluated and revealed new insights with respect to the iterative mechanism utilized by the thioesterase. Additionally, substrate tolerance towards the cyclizing nucleophile allows the formation of macrolactones instead of the native macrothiolactones. Several thiocoraline analogs were isolated and investigated for DNA-bisintercalation activity. Relaxed substrate specificity regarding the chromophore moiety enables the chemoenzymatic synthesis of the quinoxaline- and quinoline-type class of chromodepsipeptides. TioS T-TE is the first nonribosomal peptide synthetase-derived thioesterase, capable of macrothiolactonization and macrolactonization, working in an iterative manner.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19220461     DOI: 10.1111/j.1742-4658.2009.06897.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  8 in total

Review 1.  Structural insights into nonribosomal peptide enzymatic assembly lines.

Authors:  Alexander Koglin; Christopher T Walsh
Journal:  Nat Prod Rep       Date:  2009-05-22       Impact factor: 13.423

2.  First natural analogs of the cytotoxic thiodepsipeptide thiocoraline A from a marine Verrucosispora sp.

Authors:  Thomas P Wyche; Yanpeng Hou; Doug Braun; Hannah C Cohen; May P Xiong; Tim S Bugni
Journal:  J Org Chem       Date:  2011-07-20       Impact factor: 4.354

Review 3.  Explorations of catalytic domains in non-ribosomal peptide synthetase enzymology.

Authors:  Gene H Hur; Christopher R Vickery; Michael D Burkart
Journal:  Nat Prod Rep       Date:  2012-07-17       Impact factor: 13.423

4.  Natural products version 2.0: connecting genes to molecules.

Authors:  Christopher T Walsh; Michael A Fischbach
Journal:  J Am Chem Soc       Date:  2010-03-03       Impact factor: 15.419

5.  Iterative Mechanism of Macrodiolide Formation in the Anticancer Compound Conglobatin.

Authors:  Yongjun Zhou; Annabel C Murphy; Markiyan Samborskyy; Patricia Prediger; Luiz Carlos Dias; Peter F Leadlay
Journal:  Chem Biol       Date:  2015-06-18

6.  Thiocoraline activates the Notch pathway in carcinoids and reduces tumor progression in vivo.

Authors:  T P Wyche; A Dammalapati; H Cho; A D Harrison; G S Kwon; H Chen; T S Bugni; R Jaskula-Sztul
Journal:  Cancer Gene Ther       Date:  2014-11-21       Impact factor: 5.987

7.  Macrodiolide Formation by the Thioesterase of a Modular Polyketide Synthase.

Authors:  Yongjun Zhou; Patrícia Prediger; Luiz Carlos Dias; Annabel C Murphy; Peter F Leadlay
Journal:  Angew Chem Weinheim Bergstr Ger       Date:  2015-03-06

Review 8.  Biosynthetic modularity rules in the bisintercalator family of antitumor compounds.

Authors:  Javier Fernández; Laura Marín; Raquel Alvarez-Alonso; Saúl Redondo; Juan Carvajal; Germán Villamizar; Claudio J Villar; Felipe Lombó
Journal:  Mar Drugs       Date:  2014-05-09       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.